Pharmaceuticals Global News & Press Release Distribution

Akeso's Next-Generation HER3 ADC AK138D1 Combined with Ivonescimab: First Patient Enrolled in Phase Ib/II Breast Cancer Study, Advancing the IO2.0 + ADC2.0 Strategy

HONG KONG, June 15, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926) today announced that the first patient has been enrolled in the Phase Ib/II clinical study (AK138D1-202) evaluating its internally developed next-generation HER3 antibody-drug conjugate (ADC), AK138D1, as either monotherapy or in c...

2026-06-15 14:52 7222

Rznomics Presents Clinical Interim Data for RZ-001 in Recurrent Glioblastoma at ASNO 2026

* Dr. Chae-Yong Kim of Seoul National University Bundang Hospital delivers oral presentation on interim data from 10 enrolled patients * A manageable safety profile, with prolonged disease control and tumor recurrence inhibition observed in several patients SEONGNAM and SEOUL, South Korea, Ju...

2026-06-15 12:00 6331

Global Heart Hub finds women delay seeking heart care by continuing to put others first

* Heart symptoms continue to be dismissed or mistaken for other conditions, such as anxiety, new global patient-led research reveals. * Findings were presented at the European Society of Cardiology's ACNAP Congress 2026, organised by the Association of Cardiovascular Nursing & Allied Professi...

2026-06-13 00:30 4522

Simcere Pharmaceutical Enters into a Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients with Idiopathic Pulmonary Fibrosis

SHANGHAI, June 12, 2026 /PRNewswire/ -- On May 29, 2026, Pacific Time, Simcere Pharmaceutical Group Limited (2096.HK) entered into a research collaboration agreement with Stanford Medicine to jointly advance an exploratory study in the respiratory field, with the aim of developing innovative ther...

2026-06-12 14:59 7435

Akeso's Gumokimab (AK111, Anti-IL-17) Approved by NMPA for Moderate-to-Severe Plaque Psoriasis, Bolstering Its Autoimmune Disease Portfolio

HONG KONG, June 11, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced that the National Medical Products Administration (NMPA) of China has approved gumokimab(AK111), the company's internally-developed anti-IL-17 monoclonal antibody, for the treatment of adult patients with moderate-to-s...

2026-06-12 09:57 7503

Harbour BioMed Appoints Dr. Dhavalkumar Patel as Scientific Advisor

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 11, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today an...

2026-06-12 09:19 8264

Peer-reviewed publication shows that Lateral pharma's SCP drugs for neuropathic pain act via the novel target LanCL1

MELBOURNE, Australia, June 11, 2026 /PRNewswire/ -- Lateral Pharma today announced the publication of peer-reviewed research in PAIN, a leading journal dedicated to pain research, identifying Lanthionine Synthetase C-Like Protein 1 (LanCL1) as a novel therapeutic target for neuropathic pain. The ...

2026-06-11 16:22 6079

CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights

SUZHOU, China, June 11, 2026 /PRNewswire/ -- The clinical datasets presented at ASCO 2026by CStone further validate the trispecific synergistic mechanism of CS2009 and support its potential to become a next-generation immuno-oncology (I/O) backbone therapy. I. Trispecific Design Rationale and Di...

2026-06-11 14:20 6804

Caliway Unveils Latest OI25 Animal Study Data for CBL-514 in Combination with GLP-1R-Based Weight-Loss Therapies at ADA 2026, Demonstrating Dual Potential to Attenuate Post-Discontinuation Weight Regain and Improve Metabolic Health

Backed by International Authority — Caliway's latest preclinical data on its proprietary localized fat reduction candidate, CBL-514, in combination with GLP–1R–based weight–loss therapies, were presented at the American Diabetes Association 2026 Scientific Sessions (ADA 2026). The findings were d...

2026-06-11 12:54 4829

Elixiron Immunotherapeutics Reports Positive Phase 2 Interim Results for Enrupatinib: Evidence of Neuroinflammation Reduction and Early Cognitive Benefit in Alzheimer's Disease

CAMBRIDGE, Mass. and TAIPEI, June 10, 2026 /PRNewswire/ -- Elixiron Immunotherapeutics (TPEx: 7871), a clinical-stage biopharmaceutical company pioneering precision immunotherapy for neurodegenerative and autoimmune diseases, today announced positive interim results from its ongoing Phase 2 proo...

2026-06-11 10:56 7844

Harbour BioMed Appoints Dr. Luisa Salter-Cid as Scientific Advisor

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 10, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today an...

2026-06-11 09:52 4371

HkeyBio Launches "NHP Fast-PoC" Program to Deliver Low-Cost Cyno PK/PD and Developability Data Amid Rising NHP Prices

The cost-effective platform delivers rapid pharmacological validation data in cynomolgus monkeys, helping biotech firms make confident R&D decisions before committing to full-scale IND studies. BOSTON and SUZHOU, China, June 10, 2026 /PRNewswire/ -- HkeyBio, a specialized preclinical CRO focused...

2026-06-10 21:16 7374

Alteogen Showcases ALT-B4's Potential to Transform ADC Development at World ADC Summit 2026

Preclinical data demonstrate enhanced systemic exposure and bioavailability, reduced dermal toxicity, and improved safety profile in ALT-B4-enabled ADC therapy Key Points * Superior PK: Subcutaneous administration of ADCs combined with ALT-B4 demonstrated rapid absorption, enhanced systemic e...

2026-06-10 17:00 6327

Harbour BioMed Announces NMPA Acceptance of IND Application for HBM7004 for the Treatment of Advanced Solid Tumors

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 10, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today an...

2026-06-10 12:06 5698

First Patients Dosed in Phase 2 SIRIUS COPD Study of HBM9378/WIN378, a Fully Human Ultra Long-Acting Anti-TSLP Antibody

* COPD study initiation expands HBM9378/WIN378 (also known as SKB378) development into a second major respiratory disease * HBM9378/WIN378 is currently being evaluated in the Phase 2/3 POLARIS asthma study, with initial Phase 2 data expected in the second half of 2026 * HBM9378/WIN378 has th...

2026-06-09 20:23 5716

SK bioscience Joins Forces with Global Institutions to Advance Rotavirus Vaccine Development

* SK bioscience licenses vaccine technology from the U.S. Centers for Disease Control and Prevention * SK bioscience is jointly investing with the RIGHT Foundation to drive process development that enhances both efficacy and productivity * "We are committed to improving public health through...

2026-06-09 20:00 3515

SK bioscience Joins Forces with Global Institutions to Advance Rotavirus Vaccine Development

2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline

SAN FRANCISCO and SUZHOU, China, June 8, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...

2026-06-08 16:30 8984

WuXi Biologics Ireland Wins Top Honors at the 2026 Life Sciences Industry Awards

DUNDALK, Ireland, June 8, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that its Ireland site won the "Overall Excellence in Life Sciences" award, the highest recognition at the 2026 Life Scie...

2026-06-08 16:09 4261

OriCell's GPC3 CAR-T Receives NMPA Clearance for Confirmatory Phase II Trial in Late-Line Advanced Hepatocellular Carcinoma

SHANGHAI, June 7, 2026 /PRNewswire/ -- OriCell Therapeutics Holdings Limited ( The "Company" or "Oricell") ,announced that its proprietary GPC3-targeted autologous CAR-T therapy, Ori-C101, has received clearance from China's National Medical Products Administration (NMPA) to proceed into a confir...

2026-06-08 08:08 4319

Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval

NANJING, China, June 5, 2026 /PRNewswire/ -- NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors. A fusion gene is typically formed by the combination of an NTRK gene containing a kinase domain and its fusion partner gene. To date, mor...

2026-06-05 22:00 11779